7-{3-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-N-[2-(diethylamino)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide | 950733-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-{3-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-N-[2-(diethylamino)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• 英文别名: 7-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenyl)-N-(2-(diethylamino)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide；7-[3-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]-N-[2-(diethylamino)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• CAS: 950733-65-0
• 化学式: C₂₇H₂₇ClF₃N₇O₂
• 分子量: 574.005
• InChiKey: VWBONYFKEMSEAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  7-[3-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 、 N,N-二乙基乙二胺 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 二乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 7-{3-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-N-[2-(diethylamino)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
  参考文献：
  名称：

  Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors

  摘要：

  B-Raf kinase plays a critical role in the Raf-MEK-ERK signaling pathway and inhibitors of B-Raf could be used in the treatment of melanomas, colorectal cancer, and other Ras related human cancers. We have identified novel small molecule pyrazolo[1,5-a]pyrimidine derivatives as B-Raf kinase inhibitors. Structure-activity relationship was generated for various regions of the scaffold to improve the biochemical pro. le. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.129

文献信息

• Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof
  申请人：Gopalsamy Ariamala

  公开号：US20070219186A1

  公开（公告）日：2007-09-20

  The present invention relates to pyrazolo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a pyrazolo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a pyrazolo[1,5-a]pyrimidine derivative.

  本发明涉及吡唑并[1,5-a]嘧啶衍生物，包括有效量的吡唑并[1,5-a]嘧啶衍生物的组合物，以及治疗或预防癌症的方法，包括向需要的受试者施用有效量的吡唑并[1,5-a]嘧啶衍生物。
• [EN] CRYSTALLINE FORMS OF C21H22CI2N4O2<br/>[FR] FORMES CRISTALLINES DE C21H22CI2N4O2
  申请人：BIOMED VALLEY DISCOVERIES INC

  公开号：WO2016123574A1

  公开（公告）日：2016-08-04

  The present invention provides crystalline forms of a compound of formula (I). Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer. It has been discovered that crystalline forms of 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1 H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyl]amide can be prepared which exhibit improved properties, e.g. surprisingly improved stability and improved solubility characteristics. Thus, the present invention provides crystalline 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyljamide.

  本发明提供了式（I）化合物的晶体形式。还提供了包括所提供的晶体形式的药物组合物以及使用所提供的晶体形式和药物组合物治疗癌症的方法。发现可以制备4-（5-氯-2-异丙基氨基吡啶-4-基）-1H-吡咯-2-羧酸[1-（3-氯苯基）-2-羟乙基]酰胺的晶体形式，其具有改进的特性，例如惊人的稳定性和改进的溶解性特性。因此，本发明提供了晶体4-（5-氯-2-异丙基氨基吡啶-4-基）-1H-吡咯-2-羧酸[1-（3-氯苯基）-2-羟乙基]酰胺。
• [EN] CRYSTALLINE C21H22C12N4O2 MALONATE<br/>[FR] MALONATE CRISTALLIN C21H22C12N4O2
  申请人：BIOMED VALLEY DISCOVERIES INC

  公开号：WO2016123581A1

  公开（公告）日：2016-08-04

  The present invention provides a malonate salt of a compound of formula (I), which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了式(I)化合物的丙二酸盐，其为结晶盐。还提供了包括所提供的丙二酸盐的药物组合物以及使用所提供的结晶形式和药物组合物治疗癌症的方法。
• CRYSTALLINE FORMS OF C21H22Cl2N4O2
  申请人：BIOMED VALLEY DISCOVERIES, INC.

  公开号：US20170320851A1

  公开（公告）日：2017-11-09

  The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了公式（I）化合物的晶体形式。还提供包含所提供晶体形式的药物组合物以及使用所提供的晶体形式和药物组合物治疗癌症的方法。
• CRYSTALLINE C21H22Cl2N4O2 MALONATE
  申请人：BIOMED VALLEY DISCOVERIES, INC.

  公开号：US20160221988A1

  公开（公告）日：2016-08-04

  The present invention provides a malonate salt of a compound of formula (I): which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

  本发明提供了公式（I）化合物的马隆酸盐，该盐为晶体盐。还提供了包含所提供的马隆酸盐的药物组合物以及使用所提供的晶体形式和药物组合物治疗癌症的方法。